{"id":"chemotherapy-c-att","safety":{"commonSideEffects":[{"rate":"20-50%","effect":"Myelosuppression"},{"rate":"30-60%","effect":"Nausea and vomiting"},{"rate":"10-30%","effect":"Hair loss"},{"rate":"20-40%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"C-ATT is a chemotherapy drug that interferes with the DNA replication process in cancer cells, ultimately leading to cell death. This is achieved through the inhibition of topoisomerase II, an enzyme essential for DNA replication. As a result, cancer cells are unable to divide and grow, leading to tumor shrinkage and reduced cancer progression.","oneSentence":"C-ATT works by targeting and inhibiting the function of cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:30.083Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of various cancers"}]},"trialDetails":[{"nctId":"NCT00002565","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1994-05-25","conditions":"Lymphoma","enrollment":61},{"nctId":"NCT01788137","phase":"PHASE3","title":"A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2008-01","conditions":"T-cell Lymphoma Adults, Previously Untreated, High Risk","enrollment":380}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["c-ATT"],"phase":"phase_3","status":"active","brandName":"chemotherapy(c-ATT)","genericName":"chemotherapy(c-ATT)","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Chemotherapy, specifically the CHOP regimen, is used to treat high-risk, previously untreated adults with T-cell Lymphoma. The CHOP regimen typically involves a combination of bleomycin sulfate and cisplatin, along with other medications, to target and eliminate cancer cells.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}